BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 9010145)

  • 1. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).
    Simioni P; Prandoni P; Lensing AW; Scudeller A; Sardella C; Prins MH; Villalta S; Dazzi F; Girolami A
    N Engl J Med; 1997 Feb; 336(6):399-403. PubMed ID: 9010145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.
    Ridker PM; Hennekens CH; Lindpaintner K; Stampfer MJ; Eisenberg PR; Miletich JP
    N Engl J Med; 1995 Apr; 332(14):912-7. PubMed ID: 7877648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.
    Gerhardt A; Scharf RE; Beckmann MW; Struve S; Bender HG; Pillny M; Sandmann W; Zotz RB
    N Engl J Med; 2000 Feb; 342(6):374-80. PubMed ID: 10666427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.
    Manten B; Westendorp RG; Koster T; Reitsma PH; Rosendaal FR
    Thromb Haemost; 1996 Oct; 76(4):510-3. PubMed ID: 8902987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation.
    González-Porras JR; García-Sanz R; Alberca I; López ML; Balanzategui A; Gutierrez O; Lozano F; San Miguel J
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):23-8. PubMed ID: 16607075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
    Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
    Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
    Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
    N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.
    Lijfering WM; Middeldorp S; Veeger NJ; Hamulyák K; Prins MH; Büller HR; van der Meer J
    Circulation; 2010 Apr; 121(15):1706-12. PubMed ID: 20368522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.
    Kyrle PA; Minar E; Hirschl M; Bialonczyk C; Stain M; Schneider B; Weltermann A; Speiser W; Lechner K; Eichinger S
    N Engl J Med; 2000 Aug; 343(7):457-62. PubMed ID: 10950667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
    Dizon-Townson D; Miller C; Sibai B; Spong CY; Thom E; Wendel G; Wenstrom K; Samuels P; Cotroneo MA; Moawad A; Sorokin Y; Meis P; Miodovnik M; O'Sullivan MJ; Conway D; Wapner RJ; Gabbe SG;
    Obstet Gynecol; 2005 Sep; 106(3):517-24. PubMed ID: 16135581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
    Libourel EJ; Bank I; Meinardi JR; Baljé -Volkers CP; Hamulyak K; Middeldorp S; Koopman MM; van Pampus EC; Prins MH; Büller HR; van der Meer J
    Haematologica; 2002 Oct; 87(10):1068-73. PubMed ID: 12368162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K; Svensson PJ; Ohlin AK
    Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism.
    Margaglione M; D'Andrea G; Colaizzo D; Cappucci G; del Popolo A; Brancaccio V; Ciampa A; Grandone E; Di Minno G
    Thromb Haemost; 1999 Dec; 82(6):1583-7. PubMed ID: 10613638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece.
    Ioannou HV; Mitsis M; Eleftheriou A; Matsagas M; Nousias V; Rigopoulos C; Vartholomatos G; Kappas AM
    Int Angiol; 2000 Dec; 19(4):314-8. PubMed ID: 11305729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.